Penny Stock XWELL Is Up More Than 300 % Today . Why , and Should You Chase the Rally Here ?

<p>Xwell (XWEL) shares roughly quadrupled on Wednesday after the global health and wellness company announced a $31.3 million private placement agreement with American Ventures. The transaction includes the sale of 31,333 preferred Series H shares, convertible into 66.7 million common shares at an initial conversion price of $0.47.</p>
<p>Additional warrants to purchase another 66.7 million common shares accompany the offering, exercisable immediately at $0.345 per share with a three-year expiration.</p>
<h3>More News from Barchart</h3>
<ul>
<li> <a href="https://www.barchart.com/story/news/394920/microsoft-stock-just-flashed-an-ultra-rare-bullish-signal-for-options-traders?utm_source=yahoo&amp;utm_medium=syndication&amp;utm_campaign=425162&amp;utm_content=read-more-link-1">Microsoft Stock Just Flashed an Ultra-Rare Bullish Signal for Options Traders</a></li>
<li> <a href="https://www.barchart.com/story/news/396388/what-options-data-tells-us-to-expect-from-nvidia-stock-after-february-25-earnings?utm_source=yahoo&amp;utm_medium=syndication&amp;utm_campaign=425162&amp;utm_content=read-more-link-2">What Options Data Tells Us to Expect from Nvidia Stock After February 25 Earnings</a></li>
<li></li>
<li></li>
</ul>
<p>Note that today's meteoric run saw XWEL stock print a new 52-week high of $1.52.</p>
<h2>Why Xwell Stock Isn’t Worth Buying Today</h2>
<p>While the market initially reacted with an explosive rally since the capital infusion strengthens the company’s balance sheet, the structural reality is that this deal presents a huge dilution risk for existing shareholders.</p>
<p>Given that warrants are exercisable at $0.345, and Xwell stock is already trading well above that, American Ventures has an immediate incentive to exercise them and sell common shares to lock in a massive profit.</p>
<p>This makes the dilution risk particularly significant and XWEL in general a no-go for any seasoned investor, especially considering its leveraged free cash flow of negative $15.1 million, indicating material operational challenges.</p>
<h2>XWEL Shares Run the Risk of Delisting</h2>
<p>Investors are cautioned against investing in Xwell also because it remains a penny stock, which typically means extreme volatility, low liquidity, and minimal transparency.</p>
<p>XWEL has already received a compliance notice from Nasdaq; its failure to sustain today’s gains and remain above a dollar per share for another nine days would, therefore, trigger a delisting threat again.</p>
<p>And that looks rather unlikely given XWEL shares relative strength index (14-day) has soared into the mid-80s, indicating extremely overbought conditions that often precede a sharp correction.</p>
<p>In short, unless Xwell can prove it can convert this capital infusion into sustainable operational profitability and revenue growth, there’s hardly a reason for serious investors to chase momentum in this penny stock.</p>
<h2>Wall Street Isn’t Interested in Covering Xwell Inc</h2>
<p>Investors should also note that Xwell stock doesn’t currently receive coverage from Wall Street firms.</p>